Exelixis

EXELNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$13.398 B

$54.07 +3.58%

Close of 7 Aug 2026

Revenue

$2.32B

#1061 by revenue

Earnings

$782.6M

#470 by earnings

Shares outstanding

247,781,692

Latest filing cover page

P/E ratio

17.1

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#7BioNTech SEBNTX$23.5B
#8Neurocrine BiosciencesNBIX$16.6B
#9ExelixisEXEL$13.4B
#10Halozyme TherapeuticsHALO$12.2B
#11Bio-TechneTECH$11.3B

Where these numbers come from

Share counts and financials for Exelixis are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.